Ultragenyx Pharmaceutical Earnings
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Tue, Nov 3, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.64
Ultragenyx Pharmaceutical earnings summary
Ultragenyx Pharmaceutical is scheduled to report Sep/2026 earnings on Nov 3, 2026, with analysts expecting EPS of $-0.64. In its most recent report on Aug 5, 2026 (Q2 2026), RARE posted EPS of $-0.90. Revenue for the quarter was $214.0 million.
Across the last 16 reports, RARE shares moved an average of 5.0% (in either direction) in the first trading session after results, rising 8 times and falling 8 times.
Summary generated from market data by MetaCap's automated system. Methodology
RARE earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 5, 2026 | — | $-0.90 | — | +2.2% |
| May 6, 2026 | — | $-1.84 | — | -4.3% |
| Feb 18, 2026 | — | $-1.28 | — | +2.9% |
| Nov 5, 2025 | — | $-1.81 | — | +8.0% |
| Aug 6, 2025 | — | $-1.17 | — | +7.8% |
| May 7, 2025 | — | $-1.57 | — | +1.4% |
| Feb 19, 2025 | — | $-1.34 | — | +0.8% |
| Nov 6, 2024 | — | $-1.40 | — | -11.1% |
| Aug 2, 2024 | — | $-1.52 | — | -0.9% |
| May 3, 2024 | — | $-2.03 | — | -4.3% |
| Feb 21, 2024 | — | $-1.44 | — | +8.5% |
| Nov 3, 2023 | — | $-2.23 | — | -10.1% |
| Aug 4, 2023 | — | $-2.25 | — | -3.6% |
| May 5, 2023 | — | $-2.33 | — | -0.3% |
| Feb 17, 2023 | — | $-2.17 | — | -10.2% |
| Nov 3, 2022 | — | $-3.50 | — | +3.6% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.